Jie Dong1, Jian Zou, Xiao-Feng Yu. 1. Department of Gastroenterology, Huadong Hospital, Fudan University, Shanghai 200040, China.
Abstract
AIM: To quantitatively assess the relationship between coffee consumption and incidence of pancreatic cancer in a meta-analysis of cohort studies. METHODS: We searched MEDLINE, EMBASE, Science Citation Index Expanded and bibliographies of retrieved articles. Studies were included if they reported relative risks (RRs) and corresponding 95% CIs of pancreatic cancer with respect to frequency of coffee intake. We performed random-effects meta-analyses and meta-regressions of study-specific incremental estimates to determine the risk of pancreatic cancer associated with a 1 cup/d increment in coffee consumption. RESULTS: Fourteen studies met the inclusion criteria, which included 671,080 individuals (1496 cancer events) with an average follow-up of 14.9 years. Compared with individuals who did not drink or seldom drank coffee per day, the pooled RR of pancreatic cancer was 0.82 (95% CI: 0.69-0.95) for regular coffee drinkers, 0.86 (0.76-0.96) for low to moderate coffee drinkers, and 0.68 (0.51-0.84) for high drinkers. In subgroup analyses, we noted that, coffee drinking was associated with a reduced risk of pancreatic cancer in men, while this association was not seen in women. These associations were also similar in studies from North America, Europe, and the Asia-Pacific region. CONCLUSION: Findings from this meta-analysis suggest that there is an inverse relationship between coffee drinking and risk of pancreatic cancer.
AIM: To quantitatively assess the relationship between coffee consumption and incidence of pancreatic cancer in a meta-analysis of cohort studies. METHODS: We searched MEDLINE, EMBASE, Science Citation Index Expanded and bibliographies of retrieved articles. Studies were included if they reported relative risks (RRs) and corresponding 95% CIs of pancreatic cancer with respect to frequency of coffee intake. We performed random-effects meta-analyses and meta-regressions of study-specific incremental estimates to determine the risk of pancreatic cancer associated with a 1 cup/d increment in coffee consumption. RESULTS: Fourteen studies met the inclusion criteria, which included 671,080 individuals (1496 cancer events) with an average follow-up of 14.9 years. Compared with individuals who did not drink or seldom drank coffee per day, the pooled RR of pancreatic cancer was 0.82 (95% CI: 0.69-0.95) for regular coffee drinkers, 0.86 (0.76-0.96) for low to moderate coffee drinkers, and 0.68 (0.51-0.84) for high drinkers. In subgroup analyses, we noted that, coffee drinking was associated with a reduced risk of pancreatic cancer in men, while this association was not seen in women. These associations were also similar in studies from North America, Europe, and the Asia-Pacific region. CONCLUSION: Findings from this meta-analysis suggest that there is an inverse relationship between coffee drinking and risk of pancreatic cancer.
Authors: Bengt Isaksson; Fredrik Jonsson; Nancy L Pedersen; Jörgen Larsson; Maria Feychting; Johan Permert Journal: Int J Cancer Date: 2002-03-20 Impact factor: 7.396
Authors: Rachael Z Stolzenberg-Solomon; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Am J Epidemiol Date: 2002-05-01 Impact factor: 4.897
Authors: Michael B Bracken; Elizabeth Triche; Laura Grosso; Karen Hellenbrand; Kathleen Belanger; Brian P Leaderer Journal: Epidemiology Date: 2002-03 Impact factor: 4.822
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: M M H Khan; Ryoichi Goto; Kota Kobayashi; Shigeo Suzumura; Yoshie Nagata; Tomoko Sonoda; Fumio Sakauchi; Masakazu Washio; Mitsuru Mori Journal: Asian Pac J Cancer Prev Date: 2004 Jan-Mar
Authors: Apurva A Modi; Jordan J Feld; Yoon Park; David E Kleiner; James E Everhart; T Jake Liang; Jay H Hoofnagle Journal: Hepatology Date: 2010-01 Impact factor: 17.425
Authors: K A Guertin; N D Freedman; E Loftfield; R Z Stolzenberg-Solomon; B I Graubard; R Sinha Journal: Br J Cancer Date: 2015-09-24 Impact factor: 7.640